Zev Wainberg, MD
Enriched profileProfessor of Medicine (HS Clinical Professor, Medicine and Surgery); Co-Director, GI Oncology Program; Director, Early Phase Clinical Research Program · University of California, Los Angeles
Zev Wainberg is Professor of Medicine (HS Clinical Professor, Medicine and Surgery); Co-Director, GI Oncology Program; Director, Early Phase Clinical Research Program at University of California, Los Angeles. OpenAlex indexes 628 publications with 25,715 citations (h-index 72); ClinicalTrials.gov lists 8 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory. Clarivate lists Zev Wainberg as a Highly Cited Researcher (Clinical Medicine, 2025; Cross-Field, 2024).
Data verified 14 Aug 2026
Overview
Updated 16 Oct 2026
Zev Wainberg, MD, is Professor of Medicine (HS Clinical Professor, Medicine and Surgery) at University of California, Los Angeles (David Geffen School of Medicine / Jonsson Comprehensive Cancer Center). The public record shows 628 publications with 25,715 citations (h-index 72), centered on Gastric Cancer Management and Outcomes, Pancreatic and Hepatic Oncology Research, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 42 companies, 2 NIH-funded awards (2021–2026).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Gastric Cancer Management and Outcomes
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 42 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 16 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 228.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Sponsor: Jonsson Comprehensive Cancer Center
- A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
Sponsor: Novartis Pharmaceuticals
Industry payments
Updated 16 Oct 2026
42 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202527 payments$90,559openpaymentsdata.cms.gov ↗
- AstraZeneca UK LimitedProgram year202510 payments$29,300openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year202517 payments$19,138openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
59%Platinum-based Drug44.4%Oxaliplatin100%Part B, office-administered≥38 patientsMicrotubule Inhibitor11.8%Paclitaxel protein-bound particles100%Part B, office-administered≥12 patients+ 2 more classes in this area
Metabolism & gastrointestinal
36.6%Other antiemetics30.8%Fosaprepitant100%Part B, office-administered≥47 patientsSerotonin-3 Receptor Antagonist3.1%Palonosetron hcl100%Part B, office-administered≥60 patients+ 2 more classes in this area
Sensory organs
2.3%Corticosteroid2.3%Dexamethasone sodium phosphate100%Part B, office-administered≥57 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
2 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:
- Causes and Consequences of Adenosine Signaling in Pancreatic Cancer
University of California Los Angeles
FY2026$653,625R01CA290888 - Causes and Consequences of Adenosine Signaling in Pancreatic Cancer
University of California Los Angeles
FY2025$653,625R01CA290888 - Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer
University of California Los Angeles
FY2025$585,317R01CA260678
Congress activity
Updated 16 Oct 2026
233 congress contributions (2008–2026) across AACR, ASCO, ASH, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- The Randomized Phase II ARC-9 Study of Etrumadenant-Based Therapy versus Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer.
Clinical cancer research
Clinical Trial2026 - Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.
Nature medicine
Clinical Trial2026 - Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial.
Nature communications
Clinical Trial2026 - Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study.
Journal of clinical oncology
Clinical Trial2025 - Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies.
JCO precision oncology
Article2025
Most-cited works
by citation count (OpenAlex)Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/zev-wainberg-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Zev-A-Wainberg-13662742
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/WainbergZev
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/onclive_dr-zev-a-wainberg-md-a-professor-of-medicine-activity-7023651451499343874-DSv0
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/posts/ucla_one-size-fits-all-pancreatic-cancer-vaccine-activity-7368417520698998784-TxAR
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
oncologytube.com/zev-wainberg-md-wainbergzev-uclahealth-dgsomucla-ascogi22-gi22-gicancer-comments-on-enhertu-and-gi-updates
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncologytube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Tel Aviv University Sackler School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗ - Residency
Internal Medicine, Montefiore Medical Center (Albert Einstein College of Medicine)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗ - Fellowship
Hematology/Oncology, UCLA School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗ - Board Certified
Medical Oncology, American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.ucla.edu ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
- Cross-Field2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- Estelle
Abe, and Marjorie Sanders Chair in Cancer Research (endowed chair, UCLA)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucla.edu ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- Signal Transduction and Therapeutics Research Program
UCLA Jonsson Comprehensive Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗ - Clinical Advisory Board
Phanes Therapeutics
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →phanesthera.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- Research To Practice - Oncology Videos podcast
Pancreatic Cancer episode
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →videopodcast.researchtopractice.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjoncology.com ↗
- GI Oncology Now - panel moderator
biomarkers/ADCs discussion series
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gioncologynow.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Dennis Slamon, MD
University of California, Los Angeles
Richard Casaburi, MD
University of California, Los Angeles
Robert Modlin, MD
University of California, Los Angeles
John Belperio, MD
University of California, Los Angeles
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH